Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

By examining financial metrics, experts have insights into where the Australian healthcare market is today and where it might ...

ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to ...

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. Patient monitoring companies within the ...

We came across a bullish thesis on Vulcan Materials Company (VMC) on Substack by LongTermValue Research. In this article, we ...

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

The Secure Technology Alliance today announces its 2025 and 2026 Executive Committee. This group will determine the Alliance's strategic direction for the coming year and lead its efforts to address ...

BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...

A recent study conducted in Norway revealed that individuals who spend time in front of a screen before going to bed are at a ...